Participation of central descending nociceptive facilitatory systems in secondary hyperalgesia produced by mustard oil.
The present series of experiments were designed to examine a potential role for central descending pain facilitatory systems in mediating secondary hyperalgesia produced by topical application of mustard oil and measuring the nociceptive tail-flick reflex in awake rats. Topical application of mustard oil (100%) to the lateral surface of the hind leg produced a facilitation of the tail-flick reflex that was significantly reduced in spinal transected animals. Mustard oil hyperalgesia was also inhibited in animals that had received electrolytic lesions in the rostral ventromedial medulla (RVM). Intrathecal (i.t.) administration of the non-selective cholecystokinin (CCK) receptor antagonist proglumide (10 micrograms) prior to mustard oil application completely blocked both the lesser and greater hyperalgesic responses observed in spinal transected and normal animals, respectively, and produced an inhibition of the tail-flick reflex in normal animals. Administration of the selective CCKB receptor antagonist L-365260 i.t. dose-dependently inhibited mustard oil hyperalgesia (ID50 = 364 ng) at doses approximately 5-fold less than the CCKA receptor antagonist devazepide (ID50 = 1760 ng). Similar to spinal proglumide, microinjection of the neurotensin antagonist SR48692 (3.5 micrograms) into the RVM blocked mustard oil hyperalgesia and inhibited the tail-flick reflex. These data suggest that secondary hyperalgesia produced by mustard oil is mediated largely by a central, centrifugal descending pain facilitatory system which involves neurotensin in the RVM and spinal CCK (via CCKB receptors). The inhibition of the tail-flick reflex produced by mustard oil following spinal or supraspinal administration of receptor antagonists suggests concurrent activation of central descending facilitatory and inhibitory systems.
Urban
M O
MO
Department of Pharmacology, Bowen Science Building, College of Medicine, University of Iowa, Iowa City 52242, USA.
Jiang
M C
MC
Gebhart
G F
GF
D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology; D001570:Benzodiazepinones / Q000494:pharmacology; D002766:Cholecystokinin / Q000502:physiology; D003714:Denervation; D020109:Devazepide; D006727:Hormone Antagonists / Q000494:pharmacology; D006930:Hyperalgesia / Q000139:chemically induced*; D007276:Injections, Intraventricular; D008297:Male; D008526:Medulla Oblongata / Q000737:chemistry / Q000502:physiology; D008845:Microinjections; D009149:Mustard Plant; D009496:Neurotensin / Q000502:physiology; D009619:Nociceptors / Q000187:drug effects / Q000502:physiology*; D010671:Phenylurea Compounds; D010936:Plant Extracts / Q000494:pharmacology*; D010938:Plant Oils; D011377:Proglumide / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011949:Receptors, Cholecystokinin / Q000819:agonists; D018028:Receptors, Neurotensin / Q000819:agonists; D013116:Spinal Cord / Q000737:chemistry / Q000502:physiology / Q000601:surgery
D000897:Anti-Ulcer Agents; D001570:Benzodiazepinones; D006727:Hormone Antagonists; D010671:Phenylurea Compounds; D010936:Plant Extracts; D010938:Plant Oils; D011720:Pyrazoles; D011804:Quinolines; D011949:Receptors, Cholecystokinin; D018028:Receptors, Neurotensin; C079087:SR 48692; C058121:L 365260; D009496:Neurotensin; D002766:Cholecystokinin; D011377:Proglumide; D020109:Devazepide; C027793:mustard oil